Journal of Traditional Chinese Medicine ›› 2023, Vol. 43 ›› Issue (1): 51-59.DOI: 10.19852/j.cnki.jtcm.2023.01.006
• Original articles • Previous Articles Next Articles
Comparing the effects of three decoctions for coronavirus disease 2019 on severe acute respiratory syndrome coronavirus 2-related toll-like receptors-mediated inflammations
LI Ximeng, KANG Yuan, LI Wenjing, LIU Zhuangzhuang, XU Zhenlu, ZHANG Xiaoyu, CAI Runlan, GAO Yuan(
), QI Yun()
- Department of Pharmacology and Toxicology, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China
-
Received:2022-06-12Accepted:2022-09-24Online:2023-02-15Published:2023-01-10 -
Contact:GAO Yuan,QI Yun -
About author:GAO Yuan, Department of Pharmacology and Toxicology, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China. ygao@implad.ac.cn.Telephone: +86-10-57833225
QI Yun, Department of Pharmacology and Toxicology, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100193, China. yqi@implad.ac.cn
-
Supported by:Effect and Mechanisms Research of Hua-shi-Bai-Du Formula on the Cytokine Storm in COVID-19 Based on Innate and Acquired Immunity(82074091);Effects and Mechanisms research of Qing-Fei-Pai-Du-Tang on the Cytokine Storm in COVID-19 Based on TLRs Signaling(M21014);CAMS Innovation Fund for Medical Sciences (CIFMS)(2021-I2M-1-028);New Technology Research on Discovery and Evaluation of Unknown Small Molecular Effective Substances in Natural Products and 2021-I2M-1-031 (Key Technology Research on Quality Evaluation and Resource Guarantee of Rare Medicinal Plants
Cite this article
LI Ximeng, KANG Yuan, LI Wenjing, LIU Zhuangzhuang, XU Zhenlu, ZHANG Xiaoyu, CAI Runlan, GAO Yuan, QI Yun. Comparing the effects of three decoctions for coronavirus disease 2019 on severe acute respiratory syndrome coronavirus 2-related toll-like receptors-mediated inflammations[J]. Journal of Traditional Chinese Medicine, 2023, 43(1): 51-59.
share this article
Figure 1 Effects of three decoctions on R848-induced inflammatory mediators in RAW264.7 cells A: effects of three decoctions on supernatant NO; B: effects of three decoctions on supernatant MCP-1; C: effects of three decoctions on supernatant IL-6; D: effects of three decoctions on supernatant TNF-α. Cells were pretreated with QF (50, 200 or 800 μg/mL), HS (50, 200 or 800 μg/mL), XF (50, 200 or 800 μg/mL) and dexamethasone (50 μM) for 1 h and followed by R848 (50 nM) stimulation for 24 h. Dexamethasone was used as the positive control. QF: Qingfei Paidu Tang; HS: Huashi Baidu Fang; XF: Xuanfei Baidu Fang; NO: nitric oxide; MCP-1: monocyte chemoattractant protein-1; IL-6: interleukin-6; TNF-α: tumor necrosis factor α; ND: not detected. Data were presented as the mean ± standard deviation (n = 3). aP < 0.01 versus negative control; bP < 0.01 versus R848 alone.
Figure 1 Effects of three decoctions on R848-induced inflammatory mediators in RAW264.7 cells A: effects of three decoctions on supernatant NO; B: effects of three decoctions on supernatant MCP-1; C: effects of three decoctions on supernatant IL-6; D: effects of three decoctions on supernatant TNF-α. Cells were pretreated with QF (50, 200 or 800 μg/mL), HS (50, 200 or 800 μg/mL), XF (50, 200 or 800 μg/mL) and dexamethasone (50 μM) for 1 h and followed by R848 (50 nM) stimulation for 24 h. Dexamethasone was used as the positive control. QF: Qingfei Paidu Tang; HS: Huashi Baidu Fang; XF: Xuanfei Baidu Fang; NO: nitric oxide; MCP-1: monocyte chemoattractant protein-1; IL-6: interleukin-6; TNF-α: tumor necrosis factor α; ND: not detected. Data were presented as the mean ± standard deviation (n = 3). aP < 0.01 versus negative control; bP < 0.01 versus R848 alone.
Figure 2 Effects of three decoctions on poly (I:C)-induced inflammatory mediators in RAW264.7 cells A: effects of three decoctions on supernatant NO; B: effects of three decoctions on supernatant MCP-1; C: effects of three decoctions on supernatant IL-6; D: effects of three decoctions on supernatant IFN-β; E: effects of three decoctions on supernatant TNF-α. Cells were pretreated with QF (50, 200 or 800 μg/mL), HS (50, 200 or 800 μg/mL), XF (50, 200 or 800 μg/mL) and dexamethasone (50 μM) for 1 h and followed by poly (I:C) (10 μg/mL) stimulation for 24 h. Dexamethasone was used as the positive control. QF: Qingfei Paidu Tang; HS: Huashi Baidu Fang; XF: Xuanfei Baidu Fang; NO: nitric oxide; MCP-1: monocyte chemoattractant protein-1; IL-6: interleukin-6; IFN-β: interferon-β; TNF-α: tumor necrosis factor α; ND: not detected. Data were presented as the mean ± standard deviation (n = 3). aP < 0.01 versus negative control; bP < 0.01 versus poly (I:C) alone.
Figure 2 Effects of three decoctions on poly (I:C)-induced inflammatory mediators in RAW264.7 cells A: effects of three decoctions on supernatant NO; B: effects of three decoctions on supernatant MCP-1; C: effects of three decoctions on supernatant IL-6; D: effects of three decoctions on supernatant IFN-β; E: effects of three decoctions on supernatant TNF-α. Cells were pretreated with QF (50, 200 or 800 μg/mL), HS (50, 200 or 800 μg/mL), XF (50, 200 or 800 μg/mL) and dexamethasone (50 μM) for 1 h and followed by poly (I:C) (10 μg/mL) stimulation for 24 h. Dexamethasone was used as the positive control. QF: Qingfei Paidu Tang; HS: Huashi Baidu Fang; XF: Xuanfei Baidu Fang; NO: nitric oxide; MCP-1: monocyte chemoattractant protein-1; IL-6: interleukin-6; IFN-β: interferon-β; TNF-α: tumor necrosis factor α; ND: not detected. Data were presented as the mean ± standard deviation (n = 3). aP < 0.01 versus negative control; bP < 0.01 versus poly (I:C) alone.
Figure 3 Effects of three decoctions on LPS-induced inflammatory mediators in RAW264.7 cells A: effects of three decoctions on supernatant NO; B: effects of three decoctions on supernatant MCP-1; C: effects of three decoctions on supernatant IL-6; D: effects of three decoctions on supernatant IFN-β; E: effects of three decoctions on supernatant TNF-α. Cells were pretreated with QF (50, 200 or 800 μg/mL), HS (50, 200 or 800 μg/mL), XF (50, 200 or 800 μg/mL) and dexamethasone (50 μM) for 1 h and followed by LPS (10 ng/mL) stimulation for 24 h. Dexamethasone was used as the positive control. QF: Qingfei Paidu Tang; HS: Huashi Baidu Fang; XF: Xuanfei Baidu Fang; NO: nitric oxide; MCP-1: monocyte chemoattractant protein-1; IL-6: interleukin-6; IFN-β: interferon-β; TNF-α: tumor necrosis factor α; LPS: lipopolysaccharide; ND: not detected. Data were presented as the mean ± standard deviation (n = 3). aP < 0.01 versus negative control; bP < 0.01 and cP < 0.05 versus LPS alone.
Figure 3 Effects of three decoctions on LPS-induced inflammatory mediators in RAW264.7 cells A: effects of three decoctions on supernatant NO; B: effects of three decoctions on supernatant MCP-1; C: effects of three decoctions on supernatant IL-6; D: effects of three decoctions on supernatant IFN-β; E: effects of three decoctions on supernatant TNF-α. Cells were pretreated with QF (50, 200 or 800 μg/mL), HS (50, 200 or 800 μg/mL), XF (50, 200 or 800 μg/mL) and dexamethasone (50 μM) for 1 h and followed by LPS (10 ng/mL) stimulation for 24 h. Dexamethasone was used as the positive control. QF: Qingfei Paidu Tang; HS: Huashi Baidu Fang; XF: Xuanfei Baidu Fang; NO: nitric oxide; MCP-1: monocyte chemoattractant protein-1; IL-6: interleukin-6; IFN-β: interferon-β; TNF-α: tumor necrosis factor α; LPS: lipopolysaccharide; ND: not detected. Data were presented as the mean ± standard deviation (n = 3). aP < 0.01 versus negative control; bP < 0.01 and cP < 0.05 versus LPS alone.
Figure 4 Effects of three decoctions on spike-protein-induced inflammatory mediators in RAW264.7 cells A: effects of three decoctions on supernatant NO; B: effects of three decoctions on supernatant MCP-1; C: effects of three decoctions on supernatant IL-6; D: effects of three decoctions on supernatant TNF-α. Cells were pretreated with QF (50, 200 or 800 μg/mL), HS (50, 200 or 800 μg/mL), XF (50, 200 or 800 μg/mL) and dexamethasone (50 μM) for 1 h and followed by spike protein (5 μg/mL) stimulation for 24 h. Dexamethasone was used as the positive control. QF: Qingfei Paidu Tang; HS: Huashi Baidu Fang; XF: Xuanfei Baidu Fang; NO: nitric oxide; MCP-1: monocyte chemoattractant protein-1; IL-6: interleukin-6; TNF-α: tumor necrosis factor α; ND: not detected. Data were presented as the mean ± standard deviation (n = 3). aP < 0.01 versus negative control; bP < 0.01 versus spike protein alone.
Figure 4 Effects of three decoctions on spike-protein-induced inflammatory mediators in RAW264.7 cells A: effects of three decoctions on supernatant NO; B: effects of three decoctions on supernatant MCP-1; C: effects of three decoctions on supernatant IL-6; D: effects of three decoctions on supernatant TNF-α. Cells were pretreated with QF (50, 200 or 800 μg/mL), HS (50, 200 or 800 μg/mL), XF (50, 200 or 800 μg/mL) and dexamethasone (50 μM) for 1 h and followed by spike protein (5 μg/mL) stimulation for 24 h. Dexamethasone was used as the positive control. QF: Qingfei Paidu Tang; HS: Huashi Baidu Fang; XF: Xuanfei Baidu Fang; NO: nitric oxide; MCP-1: monocyte chemoattractant protein-1; IL-6: interleukin-6; TNF-α: tumor necrosis factor α; ND: not detected. Data were presented as the mean ± standard deviation (n = 3). aP < 0.01 versus negative control; bP < 0.01 versus spike protein alone.
Table 1 In vivo effects of three decoctions on the inflammatory responses in endotoxemia mice ($\bar{x}\pm s$)
| Group | n | Serum TNF-α (pg/mL) | Serum IL-6 (pg/mL) | Serum MCP-1 (pg/mL) | Rectal temperature (℃) | Relative area of loose stools |
|---|---|---|---|---|---|---|
| Normal control | 8 | 19.6±1.7 | ND | 58.4±34.2 | 36.0±0.3 | 1.0±0.8 |
| LPS | 8 | 192.0±35.4a | 156040.0±19988.3a | 102909.3±14819.6a | 34.6±0.4a | 8.2±4.3a |
| QF+LPS | 8 | 138.6±25.6b | 117190.0±28243.6b | 68762.7±18115.7b | 35.4±0.4b | 2.6±1.9c |
| HS+LPS | 8 | 143.8±16.5b | 147190.0±17889.7 | 100709.3±8428.1 | 34.9±0.4 | 6.6±2.9 |
| XF+LPS | 8 | 152.6±29.5c | 138565.0±14600 | 101816.0±22201.1 | 34.9±0.6 | 8.7±4.4 |
Table 1 In vivo effects of three decoctions on the inflammatory responses in endotoxemia mice ($\bar{x}\pm s$)
| Group | n | Serum TNF-α (pg/mL) | Serum IL-6 (pg/mL) | Serum MCP-1 (pg/mL) | Rectal temperature (℃) | Relative area of loose stools |
|---|---|---|---|---|---|---|
| Normal control | 8 | 19.6±1.7 | ND | 58.4±34.2 | 36.0±0.3 | 1.0±0.8 |
| LPS | 8 | 192.0±35.4a | 156040.0±19988.3a | 102909.3±14819.6a | 34.6±0.4a | 8.2±4.3a |
| QF+LPS | 8 | 138.6±25.6b | 117190.0±28243.6b | 68762.7±18115.7b | 35.4±0.4b | 2.6±1.9c |
| HS+LPS | 8 | 143.8±16.5b | 147190.0±17889.7 | 100709.3±8428.1 | 34.9±0.4 | 6.6±2.9 |
| XF+LPS | 8 | 152.6±29.5c | 138565.0±14600 | 101816.0±22201.1 | 34.9±0.6 | 8.7±4.4 |
| 1 | Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease pnhibitor. Cell 2020;181: 271-80. e8. |
| 2 | Junqueira C, Crespo Â, Ranjbar S, et al. FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature 2022; 606: 576-84. |
| 3 |
Sefik E, Qu R, Junqueira C, et al. Inflammasome activation in infected macrophages drives COVID-19 pathology. Nature 2022; 606: 585-93.
DOI URL |
| 4 |
Lowery SA, Sariol A, Perlman S. Innate immune and inflammatory responses to SARS-CoV-2: implications for COVID-19. Cell Host Microbe 2021; 29: 1052-62.
DOI PMID |
| 5 |
Xu G, Qi F, Li HJ, et al. The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing. Cell Discov 2020; 6: 73.
DOI PMID |
| 6 |
Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect 2020; 9: 761-70.
DOI URL |
| 7 |
Salvi V, Nguyen HO, Sozio F, et al. SARS-CoV-2-associated ssRNAs activate inflammation and immunity via TLR7/8. JCI Insight 2021; 6: e150542.
DOI URL |
| 8 |
Bortolotti D, Gentili V, Rizzo S, et al. TLR3 and TLR7 RNA sensor activation during SARS-CoV-2 Infection. Microorganisms 2021; 9: 1820.
DOI URL |
| 9 | Zhao Y, Kuang M, Li J, et al. SARS-CoV-2 spike protein interacts with and activates TLR41. Cell Res 2021; |
| 31:818-20, 825. | |
| 10 |
Shirato K, Kizaki T. SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages. Heliyon 2021; 7: e06187.
DOI URL |
| 11 | Yazdanpanah F, Hamblin MR, Rezaei N. The immune system and COVID-19: friend or foe? Life Sci 2020; 256: 117900. |
| 12 | Sallenave JM, Guillot L. Innate immune signaling and proteolytic pathways in the resolution or exacerbation of SARS-CoV-2 in Covid-19: key therapeutic targets? Front Immunol 2020; 11: 1229. |
| 13 |
Pantazi I, Al-Qahtani AA, Alhamlan FS, et al. SARS-CoV-2/ACE 2 interaction suppresses IRAK-M expression and promotes pro-inflammatory cytokine production in macrophages. Front Immunol 2021; 12: 683800.
DOI URL |
| 14 |
Liang N, Ma Y, Wang J, et al. Traditional Chinese Medicine guidelines for coronavirus disease 2019. J Tradit Chin Med 2020; 40: 891-6.
DOI PMID |
| 15 |
Shi N, Liu B, Liang N, et al. Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: a retrospective multicenter cohort study. Pharmacol Res 2020; 161: 105290.
DOI URL |
| 16 |
Wang Q, Zhu H, Li M, et al. Efficacy and safety of Qingfei Paidu decoction for yreating COVID-19: a systematic review and Meta-analysis. Front Pharmacol 2021; 12: 688857.
DOI URL |
| 17 |
Xiong WZ, Wang G, Du J, Ai W. Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19: a pilot randomized clinical trial. Integr Med Res 2020; 9: 100489.
DOI URL |
| 18 |
Pan X, Dong L, Yang L, Chen D, Peng C. Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China. Virus Res 2020; 286: 198057.
DOI URL |
| 19 |
Wang Y, Sang X, Shao R, et al. Xuanfei Baidu decoction protects against macrophages induced inflammation and pulmonary fibrosis via inhibiting IL-6/STAT3 signaling pathway. J Ethnopharmacol 2022; 283: 114701.
DOI URL |
| 20 | Li Y, Li B, Wang P, Wang Q. Traditional Chinese Medicine, Qingfei Paidu decoction and Xuanfei Baidu decoction, inhibited cytokine production via NF-κB signaling pathway in macrophages: implications for Coronavirus Disease 2019 (COVID-19) Therapy. Front Pharmacol 2021; 12: 722126. |
| 21 | Wei WL, Wu SF, Li HJ, et al. Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS. Chin J Nat Med 2021; 19: 473-80. |
| 22 | Xu X, Xia J, Zhao S, et al. Qing-Fei-Pai-Du decoction and wogonoside exert anti-inflammatory action through down-regulating USP14 to promote the degradation of activating transcription factor 2. FASEB J 2021; 35: e21870. |
| 23 |
Wang Y, Wang X, Li Y, et al. Xuanfei Baidu decoction reduces acute lung injury by regulating infiltration of neutrophils and macrophages via PD-1/IL17A pathway. Pharmacol Res 2022; 176: 106083.
DOI URL |
| 24 | National Administration of Traditional Chinese Medicine. Management specification for the decoction room of Traditional Chinese Medicine in medical institutions. Yi Zheng Si online, 2009-03-27, cited cn/yizhengsi/gongzuodongtai/2018-03-25/6577.html. |
| 25 |
Shen A, Zhou W, Xiong L, et al. Chemical profiling of Qingfei Paidu decoction by triplex off-line two-dimensional liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. J Sep Sci 2022; 45: 1162-9.
DOI PMID |
| 26 |
Wang X, Quan S, Zhang H, Song X, Zhang J, Liu D. Development and validation of a sensitive UPLC-Q-TOF-MS/MS for the measurement of nine components in rat plasma and tissues and its application to pharmacokinetics and tissue distribution studies with Xuanfei Baidu granules. Curr Drug Metab 2022; 23: 150-63.
DOI PMID |
| 27 | Zhang X, Kang Y, Li X, et al. Potentilla discolor ameliorates LPS-induced inflammatory responses through suppressing NF-κB and AP-1 pathways. Biomed Pharmacother 2021; 144: 112345. |
| 28 |
Yanagisawa S, Koarai A, Sugiura H, et al. Oxidative stress augments toll-like receptor 8 mediated neutrophilic responses in healthy subjects. Respir Res 2009; 10: 50.
DOI URL |
| 29 |
Tosar JP, Segovia M, Castellano M, et al. Fragmentation of extracellular ribosomes and tRNAs shapes the extracellular RNAome. Nucleic Acids Res 2020; 48: 12874-88.
DOI PMID |
| 30 |
Diebner HH, Reinke S, Rösen-Wolff A, Winkler S. A linetic response model for standardized regression analyses of inflammation-triggered hypothermic body temperature-time courses in Mice. Front Physiol 2021; 12: 634510.
DOI URL |
| 31 |
Moriez R, Salvador-Cartier C, Theodorou V, Fioramonti J, Eu-tamene H, Bueno L. Myosin light chain kinase is involved in lipo-polysaccharide-induced disruption of colonic epithelial barrier and bacterial translocation in rats. Am J Pathol 2005; 167: 1071-9.
DOI URL |
| 32 | Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell2020;181: 1036-45. e9. |
| 33 |
Kempuraj D, Selvakumar GP, Ahmed ME, et al. COVID-19, mast cells, cytokine storm, psychological stress, and neuro-inflammation. Neuroscientist 2020; 26: 402-4.
DOI URL |
| 34 |
Mabrey FL, Morrell ED, Wurfel MM. TLRs in COVID-19: how they drive immunopathology and the rationale for modulation. Innate Immun 2021; 27: 503-13.
DOI URL |
| 35 | Galván-Román JM, Rodríguez-García SC, Roy-Vallejo E, et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study. J Allergy Clin Immunol 2021;147: 72-80. e8. |
| 36 |
Higgins PG, Phillpotts RJ, Scott GM, Wallace J, Bernhardt LL, Tyrrell DA. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob Agents Chemother 1983; 24: 713-5.
DOI PMID |
| 37 |
Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003; 290: 3222-8.
PMID |
| 38 |
Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N, Type 1 interferons as a potential treatment against COVID-19. Antiviral Res 2020; 178: 104791.
DOI URL |
| 39 |
Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res 2020; 179: 104811.
DOI URL |
| 40 | Wang K, Yan HY, Wu S, Wang HQ, Li YH, Jiang JD. Inhibitory effect of Qing-Fei-Pai-Du decoction on coronavirus in vitro. Acta Pharmaceutica Sinica 2021; 56: 1400-8. |
| 41 | Zhang SY, He GL, Lu FG, et al. Mechanism research of antiinfluenza virus of ephedra decocted earlier Maxing Shigan decoction from the expression level of IFN-α/β protein mediated by TLR7/8. Zhong Hua Zhong Yi Yao Za Zhi 2019; 34: 1188-93. |
| 42 |
Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020; 369: 718-24.
DOI PMID |
| 43 |
Schreiber G. The role of type I interferons in the pathogenesis and treatment of COVID-19. Front Immunol 2020; 11: 595739.
DOI URL |
| 44 | Hasselbalch HC, Skov V, Kjær L, et al. COVID-19 as a mediator of interferon deficiency and hyperinflammation: rationale for the use of JAK1/2 inhibitors in combination with interferon. Cytokine Growth Factor Rev 2021; 60: 28-45. |
| [1] | JIN Tao, ZHOU Qian, SHEN Jichen, ZHANG Zhizhong, LIAN Xiaoyuan. Caffeic acid 3,4-dihydroxyphenethyl ester prevents colorectal cancer through inhibition of multiple cancer-promoting signal pathways in 1,2-Dimethylhydrazine/dextran sodium sulphate mouse model [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 70-77. |
| [2] | LIU Huihui, FENG Jun, LIU Jianhe, CHENG Choufu, HU Guoheng. Efficacy of Jiangzhi Xiaoban tablet (降脂消斑片) on toll-like receptor 4/nuclear factor-kappa B/nod-like receptor protein 3 signaling pathway in mice with atherosclerosis induced by high-fat diet [J]. Journal of Traditional Chinese Medicine, 2024, 44(1): 88-94. |
| [3] | FAN Rong, HE Haoyu, TANG Tao, CUI Hanjin. Long-term effects of Qingfei Paidu decoction (清肺排毒汤) in patients with coronavirus disease 2019 acute pneumonia after treatment: a protocol for systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(6): 1068-1071. |
| [4] | LI Zhihao, HAN Wenjun, SONG Xiuling, LI Yan, CHEN Yuelai. Electroacupuncture stimulating Zhongji (CV3), Guanyuan (CV4), and bilateral Dahe (KI12) attenuates inflammation in rats with chronic nonbacterial prostatitis induced by estradiol through inhibiting toll-like receptor 4 pathway [J]. Journal of Traditional Chinese Medicine, 2023, 43(5): 963-972. |
| [5] | SUN Wu, ZHAO Yuwei, LIAO Liang, ZHAO Zhonghui, CHEN Shiqi, YAN Xiaoling, WANG Xueyao, CHAO Guojun, ZHOU Jian. Effectiveness and safety of Xuebijing injection for patients with coronavirus disease 2019: a systematic review and Meta-analysis [J]. Journal of Traditional Chinese Medicine, 2023, 43(4): 631-639. |
| [6] | HAN Yunpeng, YU Wentao, ZHANG Ying, XU Huazhou, DENG Guoxing, FANG Chaoyi. Qinghua decoction (清化饮) improves chronic nonbacterial prostatitis possibly via regulating the chromogranin A/nerve growth factor/tyrosine kinase A signaling pathway mediated by inflammatory factors [J]. Journal of Traditional Chinese Medicine, 2023, 43(4): 695-703. |
| [7] | ZHANG Yuehong, SHAO Xianzhi, ZHAO Qianlong, ZHAN Hualong, ZHANG Jianhua, DU Sisi, CHEN Jing, LIU Yingfang, ZHOU Haiwang, CHEN Xinsheng, HONG Ying, LIAN Fengmei, TONG Xiaolin, BA Yuanming. Effectiveness of Xiangsha Liujun pills (香砂六君丸) on decreased digestive function in convalescent patients of coronavirus disease 2019: a randomized, double blind, placebo controlled clinical trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 552-558. |
| [8] | XU Guihua, CHEN Feifei, ZHANG Wei, WU Yingen, CHEN Xiaorong, SHI Kehua, WANG Zhenwei, SHI Miaoyan, ZHANG Xing, LU Yunfei, YUAN Weian, LYU Hua, CHEN Xuan. Effectiveness of Traditional Chinese Medicine on coronavirus disease 2019 in 92 patients: a retrospective study [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 582-587. |
| [9] | YANG Yang, YUAN Haining, JIA Hongxiao, NING Yanzhe, WANG Di, ZHANG Lei, YAN Kaijuan, GUO Yumeng, WANG Fei, SUN Weishuang, CHEN Pei. Therapy of replenishing Yin and regulating Yang for manic episode in bipolar disorder: study protocol for a prospective, double-blind, randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 594-601. |
| [10] | YANG Zhangjie, WANG Yuxin, CHEN Dongmei, ZHAO Shuai, HU Na, MA Lianghong, MA Huiming. Gouqizi (Fructus Lycii) seed oil reduces D-galactose induced inflammation in testis of rats via Janus kinase 1/signal transducerand activator of transcription 1/nuclear factor-κB in vitro and in vivo [J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 265-273. |
| [11] | XIE Jing, BI Zheng, WANG Sihai, SHEN Guoming, FANG Zhaohui. Danzhi Jiangtang capsule (丹蛭降糖胶囊) reduces renal injury in rats with diabetes induced by high fat diet and streptozotocin via downregulating toll-like receptor 4-nuclear factor-κB pathway and apoptosis [J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 312-321. |
| [12] | YANG Cunqing, LIAN Fengmei, YANG Guiping, HUANG Yufeng, ZHANG Shuangbin, WANG Jianghua, ZHOU Jing, GUO Dongqing, SHEN Chuanyun, YE Tiansong, FU Aojie, LI Xiaoli, CHEN Le, ZHANG Huifeng, TU Qiyin, WANG Ying, YANG Wenzhe, TONG Xiaolin, BA Yuanming. Effectiveness of Xiaoyao capsule (逍遥丸) on sleep disorders and mood disturbance in patients in recovery from coronavirus disease 2019: a randomized controlled trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(2): 343-351. |
| [13] | ZHANG Yuehong, DONG Dandan, YAN Youqin, ZHANG Hao, WANG Guangli, ZHOU Wei, LI Wei, QIU Li, LI Tingming, LIU Quan, XIA Ping, MAO Lina, YANG Danlin, YANG Lu, LIAN Fengmei, TONG Xiaolin, BA Yuanming. Effectiveness and safety of Jinshuibao capsules (金水宝胶囊) in treatment of residual cardiopulmonary symptoms in convalescent patients of coronavirus disease 2019: a pilot randomized, double-blind, placebo-controlled clinical trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(1): 134-139. |
| [14] | AN Xuedong, MAO Lina, XIA Ping, SU Wen, WANG Beibei, KOU Leiya, ZHANG Zequan, QI Meng, HU Song, CHEN Jing, LI Xiujuan, LIU Jinwei, ZHOU Juan, QIAO Jie, LUO Dan, LUO Guangwei, YAN Youqin, YANG Guiping, DONG Dandan, ZHOU Wei, TAO Junxiu, JIN De, TONG Xiaolin, WEI Li. Effects of Shengmai Yin (生脉饮) on pulmonary and cardiac function in coronavirus disease 2019 convalescent patients with cardiopulmonary symptoms: a randomized, double blind, multicenter control trial [J]. Journal of Traditional Chinese Medicine, 2023, 43(1): 140-145. |
| [15] | DING Yanping, DONG Xiaoqing, MA Yifan, CHEN Lili, ZHOU Jie, LI Xinyan, SHAO Baoping. Astragaloside IV plays a role in reducing radiation-induced liver inflammation in mice by inhibiting thioredoxin-interacting protein/nod-like receptor protein 3 signaling pathway [J]. Journal of Traditional Chinese Medicine, 2023, 43(1): 87-94. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
